The Billion Cell Atlas, backed by Eli Lilly, MSD and AstraZeneca, maps mechanisms to support informed drug discovery.

SAN DIEGO, Oct. 15, 2025 /PRNewswire/ -- Illumina, Inc. (ILMN) today announced that GeneDx, a leader in genetic testing for rare diseases, is piloting Illumina's emerging constellation mapped read ...

Expands pharma access to large omics datasets to advance target discovery and drug development SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Illumina, Inc. (ILMN) today announced the launch of BioInsight, a ...

Illumina on Tuesday unveiled what it calls the world’s largest functional cell dictionary that, when paired with artificial ...

SAN DIEGO, June 24, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the successful completion of the spin-off of GRAIL. This milestone follows the company's previously announced ...

During the meeting, Steve Barnard, PhD, Illumina’s CTO will provide new details about the company’s constellation mapped read technology. He will be joined by Niall Lennon, PhD, chair and CSO of Broad ...

Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

How would it feel to know the work you do each day is impacting human health on a global scale? As genomics enables a new era of heath care, Illumina technology is empowering personalized care – ...

Illumina Taiwan Biotechnology Co., Ltd., and Precision Medicine Asia, Limited (PREMIA), a leading Asian cancer ...